Sidley represented OnCusp Therapeutics, Inc., a biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide, in the oversubscribed US$100 million (more than RMB700 million) Series A financing round, which was co-led by Novo Holdings, OrbiMed, and F-Prime Capital, alongside Sofinnova Investments, Catalio Capital Management, Marshall Wace, Forge Life Science Partners, Blackbird BioVentures, CJNV BioVenture, BioTrack Capital, and others.
The proceeds from this financing will be used to advance CUSP06, an ADC targeting CDH6, toward clinical proof-of-concept. Additionally, the capital will aid in expanding the OnCusp portfolio and team.
The Sidley team was led by partners Ruchun Ji (Shanghai) and Geoffrey Levin (New York). Other team members included partners Eric Wolf (New York) and James Mendenhall (Washington, D.C.), managing associates Yahel Kaplan and Joel Lifshitz (New York), senior managing associate Carys Golesworthy (Washington, D.C.), associate Rui Liu (Shanghai), and law clerk Milly Kim (New York).
Sidley’s Global Life Sciences practice, which comprises more than 200 dedicated lawyers globally, offers cross-disciplinary, full-service solutions for life science clients, ranging from M&A and private equity, licensing and collaboration transactions, capital markets, regulatory compliance and enforcement, and dispute resolutions, assisting biotech and pharmaceutical clients around the world. Sidley’s China Life Sciences practice, an integral part of the firm’s Global Life Sciences practice, is the only Band One international firm ranked by Chambers Asia Pacific/Greater China Region for 14 consecutive years.
